BPC-157
What is BPC-157 and what does it actually do?
BPC-157 is a synthetic peptide made from 15 amino acids and is also known as Body Protection Compound 157. It has become one of the best-known peptides in the recovery space, particularly in discussions about tendon injury, ligament damage, muscle recovery and gastrointestinal research. Interest is high, but the available evidence is weighted heavily toward animal and laboratory studies rather than controlled human trials.
There is real research behind that interest. BPC-157 has been investigated across a surprisingly wide range of experimental injury models, including damaged Achilles tendons, surgically injured ligaments, crushed and transected muscle, tendon-to-bone injuries and gastrointestinal damage. Researchers have repeatedly reported effects connected with healing, tissue organisation, blood-vessel formation and functional recovery.
The detail that matters is where most of that research happened. The large majority of positive findings come from animal or laboratory work. Human research does exist and has grown in the last few years, but it is still small and early. That puts BPC-157 in an unusual position: there is considerably more experimental research behind the interest than you might assume, but considerably less human evidence than the confidence of many online claims would suggest.
What is BPC-157 made from?
BPC-157 contains 15 amino-acid residues arranged in a defined chain. The word pentadecapeptide simply means a peptide containing fifteen amino-acid residues. Its commonly reported sequence is GEPPPGKPADDAGLV, and its molecular mass is about 1,419 daltons.
The BPC part of the name comes from Body Protection Compound. Early researchers studying protective substances associated with gastric juice described a larger protein fraction called BPC and characterised BPC-157 as a 15-amino-acid sequence associated with that research. Modern BPC-157 used experimentally is synthesised rather than extracted from somebody's stomach.
That origin helps explain something that can otherwise seem odd about BPC-157. Today it is often discussed as a recovery or sports peptide, yet much of its research history began with the stomach and digestive system. Musculoskeletal research came later as investigators began testing whether the repair-related effects they were observing appeared in other tissues.
You may also see BPC-157 described as Bepecin or PL-14736 in older material. Those names are useful when searching the literature because some of the gastrointestinal development work used the PL-14736 name rather than the term that dominates online discussion today.
How was BPC-157 discovered?
BPC-157 did not begin as a bodybuilding or recovery product. Its research history traces back to scientists in Zagreb studying the way the stomach protects itself from injury. The broader research programme focused on a substance referred to as Body Protection Compound, or BPC, associated with gastric juice and tissue protection.
In 1993, researchers described the 15-amino-acid sequence that became known as BPC-157. The early work was built around ideas such as gastric protection, organ protection and the response of damaged tissue to stress. That is why some of the oldest BPC-157 papers have much more to do with stomach injury than tendons or gym recovery.
Researchers then began testing whether the same repair-related effects appeared outside the digestive system. That moved the research into skin, blood vessels, muscle, tendon, ligament and bone models. Over time, the musculoskeletal studies became the part of the literature that attracted the most attention from sports and recovery communities.
The modern online story therefore runs almost backwards from the scientific history. Many people first encounter BPC-157 as a peptide associated with injuries and recovery, then discover the gut research later. In the published literature, the gastrointestinal and tissue-protection work came first.
How is BPC-157 manufactured?
The BPC-157 used in modern research is synthetic. It is not collected from gastric juice. Manufacturers reproduce the same 15-amino-acid sequence chemically by joining amino acids together in the required order.
FDA traced the original published synthesis back to researchers at the University of Zagreb in the early 1990s. The researchers used a form of solid-phase peptide synthesis involving Fmoc-protected amino acids attached to a polymer support. Once the sequence had been assembled, the peptide was separated from the support and the raw mixture was purified using high-performance liquid chromatography.
Solid-phase peptide synthesis remains one of the standard ways of manufacturing synthetic peptides. The basic idea is simple even if the chemistry is not: hold the growing peptide chain in place, add the next amino acid, remove its temporary protective group, and repeat until the complete sequence has been built.
The difficult part is not simply producing something with the right name. Peptide synthesis can also create incomplete chains, closely related peptide fragments, residual chemicals and aggregates. That is why purification, identity testing and control of impurities matter as much as the headline purity percentage shown on a certificate.
What does lyophilised mean?
Lyophilisation is freeze-drying. Water is removed from the peptide preparation to leave a dry material, often seen as a powder or compact material inside a vial. It is a physical presentation of the peptide, not a different peptide.
What does purification do?
After synthesis, the desired peptide has to be separated from incomplete sequences and other reaction products. The original BPC-157 synthesis described purification by high-performance liquid chromatography to greater than 95% purity.
Free base versus acetate
You may see both BPC-157 free base and BPC-157 acetate. FDA treats them as distinct bulk drug substances rather than interchangeable names for exactly the same material. Salt form can affect physical and chemical behaviour, including properties such as solubility and stability.
Why does product quality matter?
Two products labelled BPC-157 are not automatically chemically identical in every respect. Identity, peptide-related impurities, aggregates, residual manufacturing chemicals and microbiological quality can all matter when characterising a peptide product.
What forms does BPC-157 come in?
The BPC-157 name appears on several very different product formats. Seeing a peptide offered in a particular form tells you how that product is presented. It does not, by itself, tell you that the route has been clinically validated.
Lyophilised peptide vials
A common research-market format is dry lyophilised peptide in a vial. FDA describes BPC-157 free base as a white to off-white lyophilised powder. The vial normally states the total mass of peptide rather than the concentration of any later solution.
Capsules and tablets
FDA identified BPC-157 being marketed in oral capsule and tablet products and also reviewed proposed compounded oral capsules. An oral product and an injectable product can carry the same BPC-157 name while creating very different exposure.
Injectable solutions
Subcutaneous injectable formulations were among the dosage forms submitted in earlier compounding nominations reviewed by FDA. Injectable products introduce additional quality considerations such as sterility, endotoxins and particulates.
Nasal sprays
A metered nasal spray was also proposed in the material reviewed by FDA. For a nasal product, the device itself matters because pump delivery, dose uniformity, spray pattern and droplet size affect what is actually delivered.
Suppositories and transdermal creams
FDA also reviewed proposals involving rectal suppositories and transdermal cream. These formats illustrate how broad the commercial presentation of BPC-157 has become, even though the supporting human evidence is not equally developed for each route.
Free base and acetate
The label may also identify BPC-157 free base or BPC-157 acetate. That distinction is separate from whether the finished product is a vial, capsule or spray. It describes the chemical form of the peptide material itself.
What does a BPC-157 vial actually tell you?
If a vial is labelled 5 mg BPC-157, the 5 mg describes the stated total mass of peptide in that vial. It does not mean the solution concentration is 5 mg/mL, and it does not tell you how much liquid would occupy any particular syringe measurement.
Milligrams and micrograms are both units of mass. One milligram equals 1,000 micrograms, so a vial labelled 5 mg represents 5,000 micrograms of stated peptide mass. Converting between those units does not change the amount present. It only changes how the number is written.
Concentration is different from total mass. Concentration describes how much peptide is present in a given volume of solution. Until a liquid volume is known, a dry 5 mg vial has a total peptide amount but no mg/mL solution concentration.
That distinction sounds basic, but it is the source of a lot of confusion around peptide calculations. It is also why Orentra keeps vial amount, solution volume, concentration and syringe measurement as separate values in the calculators rather than treating them as interchangeable numbers.
Start with vial amount, liquid volume and desired peptide amount to understand concentration and solution volume.
Start with a solution measurement and work backwards to understand how much peptide it represents.
Understand how vial size, number of vials and a research schedule affect total supply.
Why does BPC-157 get so much attention?
Recovery is the obvious reason. Tendons and ligaments can be particularly frustrating injuries because they often recover slowly, blood supply can be limited and returning to normal training may take much longer than the person expected. Anything associated with faster connective-tissue repair is therefore going to attract attention among athletes, lifters and people dealing with persistent injuries.
BPC-157 became interesting because the experimental results were not limited to one obscure injury model. Researchers have reported positive findings in rat Achilles tendon injuries, medial collateral ligament transection, crushed muscle, completely transected muscle and injuries at the junctions where muscle, tendon and bone connect.
In the 2006 Achilles tendon-to-bone study, researchers detached the tendon from the heel bone of rats. Animals receiving BPC-157 showed improvements in walking-related function, load to failure, stiffness, collagen organisation and vascular appearance compared with controls. These are meaningful measures in an animal healing experiment because they look at both what the tissue looks like and whether it can actually tolerate force.
Ligament work has produced a similar theme. In a rat model where the medial collateral ligament was surgically transected, BPC-157-treated animals showed improvements across functional, biomechanical, macroscopic and histological measures over the healing period. The researchers tested several routes in the animal model, including intraperitoneal, oral and local administration.
The muscle literature is also broader than a single paper. Studies have looked at crushed gastrocnemius muscle, completely transected quadriceps muscle and damaged myotendinous junctions. Across these models, researchers reported changes in healing, tissue structure, muscle function and recovery of movement.
A newer study published in July 2026 looked at Achilles tendon healing in rats and compared BPC-157, TB-500, the two together and a control group. BPC-157 was associated with some improved measures, but several of its differences did not reach statistical significance. TB-500 showed the clearest biomechanical difference in that particular experiment, and combining the peptides did not produce an obvious additional benefit. That is a useful reminder that newer studies do not always reproduce the strongest interpretation of older work.
This is why the sensible way to describe BPC-157 is not that it has been proven to heal injuries, but also not that the recovery interest is based on nothing. There is a real and fairly broad experimental literature. The unanswered part is how much of that translates into predictable results in people.
Where is the research focused?
Tendons and ligaments
Achilles tendon, tendon-to-bone and ligament injury models make up an important part of the BPC-157 recovery literature. Researchers have measured tissue appearance, collagen organisation, strength and functional recovery.
Muscle and tissue junctions
BPC-157 has been tested in crushed muscle, completely transected muscle and damaged myotendinous junctions. These studies looked at both structural healing and recovery of movement.
Gut and gastrointestinal injury
The peptide has a long gastrointestinal research history. Experimental studies have covered the stomach, oesophagus, intestine and other digestive-system injury models.
Blood vessels and repair signalling
Researchers have investigated angiogenesis, VEGFR2 signalling, fibroblast migration, nitric-oxide pathways and growth-hormone receptor expression as possible pieces of the repair story.
Why is BPC-157 also associated with the gut?
The recovery conversation can make BPC-157 sound as though it began life as a sports peptide. It did not. The early research was closely connected with gastric protection and the idea that substances associated with the stomach might help tissues cope with injury and stress.
Over the years, experimental work expanded across gastric ulcers, oesophageal injury, intestinal damage, anastomoses, fistulas and other gastrointestinal models. Reviews from the Zagreb research group describe effects involving mucosal protection, vascular function and healing throughout several parts of the digestive tract.
There was also human development work around ulcerative colitis under the PL-14736 name. FDA's 2026 review identified an older multicentre, randomised, double-blind, placebo-controlled Phase II study reported in conference material. Fifty-three people were randomised overall, with roughly half receiving BPC-157 as a rectal enema once daily for two weeks. FDA concluded that the limited information available was not enough to establish effectiveness.
That history matters because it changes how you interpret BPC-157. The peptide did not move from bodybuilding culture into science. The direction was largely the other way around: experimental gastric and tissue-protection research existed first, and online recovery culture later concentrated heavily on the musculoskeletal findings.
What are researchers looking at?
There is no single proven mechanism that explains every reported BPC-157 effect. Instead, experimental studies point toward several overlapping processes involved in healing and vascular function. These mechanisms are interesting because they can help explain the animal findings, but demonstrating a pathway in cells or rats is not the same thing as demonstrating a useful clinical effect in people.
Fibroblast movement and survival
Fibroblasts help build and maintain connective tissue. In cultured rat tendon fibroblasts, BPC-157 increased migration and spreading and improved survival under oxidative stress. Researchers linked part of this effect to FAK-paxillin signalling, which is involved in how cells attach and move.
Blood-vessel formation
Healing tissue needs blood supply. Experimental work using endothelial cells, a chick membrane model and rat hind-limb ischaemia found increased vessel formation and signalling through VEGFR2, Akt and eNOS. This is one reason angiogenesis appears repeatedly in explanations of BPC-157 research.
Growth-hormone receptor signalling
A laboratory study using rat tendon fibroblasts found that BPC-157 increased growth-hormone receptor expression. When growth hormone was then added, downstream signalling and cell proliferation increased. This does not mean BPC-157 is growth hormone. It suggests one possible way it could change how tendon cells respond to an existing biological signal.
Nitric oxide and vascular responses
The nitric-oxide system affects blood vessels, circulation and several cellular responses to injury. BPC-157 research has repeatedly investigated interactions with nitric-oxide-related pathways. The VEGFR2 study, for example, reported activation of the VEGFR2-Akt-eNOS pathway.
Collagen and tissue organisation
Several injury studies did more than simply record whether an animal looked better. Researchers examined collagen fibres, tissue organisation and biomechanical strength. In tendon and ligament models, BPC-157-treated tissue often showed more organised healing alongside improved mechanical measurements.
Pharmacokinetics
Animal pharmacokinetic work found a plasma half-life below 30 minutes, rapid metabolism into smaller peptide fragments and elimination through urine and bile. That relatively short measured exposure sits alongside reports of biological effects lasting much longer, which researchers still need to explain properly.
What has actually been studied?
The easiest way to misunderstand BPC-157 is to count papers without asking what kind of evidence they contain. A rat tendon experiment, a laboratory cell study and a controlled human trial do not answer the same question. Orentra keeps them separate so you can see where the evidence is deep and where it is still thin.
Human evidence is no longer literally absent, but it remains small. FDA's 2026 review identified human exposure in ulcerative-colitis development, a knee-pain chart review, an interstitial-cystitis pilot and a two-person intravenous safety pilot. These studies used very different routes and were investigating very different questions.
The knee study is probably the human report most relevant to the recovery audience. Researchers retrospectively reviewed people who had received an intra-articular BPC-157 injection, alone or with thymosin beta-4. Of the 12 people who received BPC-157 alone and were contacted, 11 reported significant improvement in knee pain. Seven of the 12 were reported in the later systematic review as having relief lasting more than six months.
That sounds interesting, but the study design matters. There was no placebo group, the causes of knee pain varied, follow-up was retrospective and no standardised imaging or objective functional tool was used to demonstrate tissue repair. The study therefore provides a human signal worth investigating, not a clinical answer.
The interstitial-cystitis pilot involved 12 women with moderate to severe symptoms who had not responded to pentosan polysulfate. The study reported substantial improvement after a single procedure involving a total of 10 mg BPC-157 placed into the bladder wall, and no adverse events were reported. Again, there was no comparison group and the study was small.
The 2025 intravenous pilot was even smaller: two adults. They received 10 mg on one study day and 20 mg on the next. Researchers reported no side effects and no meaningful changes in the heart, liver, kidney, thyroid, blood-glucose or haematological measures they checked. Two people can show that those two people tolerated those infusions under those conditions. They cannot establish a general safety profile.
This is where the BPC-157 evidence base becomes much larger. The 2025 orthopaedic systematic review screened 544 records and included 36 musculoskeletal studies. Thirty-five were preclinical and only one was clinical. Across the animal literature, researchers reported improvements in functional, structural or biomechanical outcomes in models involving muscle, tendon, ligament and bone.
The breadth is important. Positive findings are not confined to repeated versions of the exact same experiment. Achilles tendon transection, Achilles tendon-to-bone detachment, medial collateral ligament injury, muscle crush, complete muscle transection and damaged tissue junctions have all been studied.
At the same time, preclinical depth should not be confused with clinical certainty. Rodent injury models are deliberately controlled experiments. Human injuries are more variable, people have different medical histories and the amounts, routes and preparations used outside a laboratory may be very different from the research conditions.
The July 2026 Achilles study is a useful example of why continuing to update this page matters. It still found signs that BPC-157 influenced tendon repair, but some headline differences were numerical rather than statistically significant. New evidence can strengthen, weaken or simply add nuance to the story.
Laboratory studies try to answer a different question: if BPC-157 appears to change healing in animals, what might be happening at a cellular level? Tendon-cell experiments have investigated fibroblast movement, survival, cell spreading and signalling pathways associated with tissue repair.
Other research has examined growth-hormone receptor expression and vascular signalling. A 2014 tendon-fibroblast study reported increased growth-hormone receptor expression, while a later angiogenesis study reported increased VEGFR2 signalling and blood-vessel-related responses.
These studies help make the larger research story biologically plausible, but plausibility is not proof of effectiveness. A compound can affect an interesting pathway in a laboratory without ultimately becoming a useful medicine.
What has actually happened in people?
Ulcerative colitis development
- Who?
- 53 people randomised overall, approximately half receiving BPC-157
- What happened?
- Older Phase II conference material described rectal BPC-157 use in mild-to-moderate ulcerative colitis.
- What should you know?
- The evidence is available mainly through conference reporting and regulator review rather than a complete modern peer-reviewed clinical publication.
Knee pain chart review
- Who?
- 17 identified, 16 contacted, 12 received BPC-157 alone
- What happened?
- Eleven of the 12 contacted participants who received BPC-157 alone reported significant improvement in knee pain.
- What should you know?
- Retrospective, uncontrolled, mixed causes of knee pain and largely subjective follow-up.
Interstitial cystitis pilot
- Who?
- 12 women
- What happened?
- All participants reported substantial improvement after the procedure and no adverse events were reported.
- What should you know?
- Small, uncontrolled, single-centre pilot using a procedure-specific route.
Intravenous safety pilot
- Who?
- 2 adults
- What happened?
- No reported side effects or meaningful changes in the laboratory and vital-sign measures collected.
- What should you know?
- Only two participants, both of whom had received IV BPC-157 previously.
How has BPC-157 actually been delivered?
The route matters. Swallowing a compound, placing it into a joint and delivering it directly into the bloodstream are not equivalent experiments. BPC-157 research has used several routes, which is one reason a single number taken from one study cannot automatically be applied to another.
Rectal
Human researchEarlier ulcerative-colitis development used BPC-157 rectally as an enema. FDA reviewed conference material describing once-daily rectal exposure for two weeks. This route was being studied specifically in the context of bowel disease.
Intra-articular
Human reportThe knee-pain chart review involved BPC-157 being placed directly into the knee joint. That is what intra-articular means. It is a local joint route and should not be treated as equivalent to oral, intravenous or subcutaneous exposure.
Intravesical
Human pilotThe interstitial-cystitis pilot involved administration into the bladder during a procedure. This is called intravesical administration and was chosen because the research question involved the bladder itself.
Intravenous
Human safety pilotThe two-person 2025 pilot delivered BPC-157 directly into the bloodstream by intravenous infusion. Researchers used this setting to observe short-term tolerability and blood measurements rather than to test an injury-recovery outcome.
Oral / intragastric
Mostly preclinicalOral and intragastric exposure appears repeatedly in the animal literature, particularly in the gastrointestinal and injury research. Animal oral exposure should not automatically be interpreted as evidence for the effectiveness of commercially marketed human capsules.
Intraperitoneal and local
PreclinicalMany animal experiments used intraperitoneal administration, meaning delivery into the abdominal cavity, or local administration near the experimental injury. These are common experimental routes in animal research but do not directly map onto ordinary human use.
Subcutaneous
Commercially proposedSubcutaneous BPC-157 is widely discussed in the research-product market and was one of the compounded dosage forms proposed to FDA. FDA noted that the human clinical evidence it identified did not establish the nominated subcutaneous route for the uses it reviewed.
Nasal and transdermal
Proposed formulationsNasal spray and transdermal cream have also appeared in proposed compounded formulations. The existence of a product format is not the same thing as having human trials showing what exposure or effect that route produces.
How has BPC-157 actually been studied?
Human studies have used very different amounts, routes and research questions. That is useful context when you see a single BPC-157 number repeated online as though it came from an established clinical protocol.
| Research | Subjects | Amount reported | Route | Period |
|---|---|---|---|---|
| Ulcerative colitis study | 53 randomised overall, approximately 26 receiving BPC-157 | 80 mg | Rectal enema | Once daily for 2 weeks |
| Knee pain chart review | 17 identified | 2 to 4 mg | Intra-articular | 1 to 2 administrations |
| Interstitial cystitis pilot | 12 women | 10 mg total | Intravesical / bladder wall | Single procedure |
| IV safety pilot | 2 adults | 10 mg then 20 mg | Intravenous | Two study days |
These are amounts and routes reported in human research. They describe what researchers did in those specific studies. They are not suggested starting amounts, personal-use protocols or evidence that the same amount is appropriate for a different route or purpose.
Where are the gaps?
BPC-157 has enough research to generate interesting questions. It does not yet have enough human research to answer several of the most practical ones.
How well do the animal results translate to people?
This is the big question. Tendon and muscle healing in rodents can identify biological effects worth studying, but it cannot tell us how much benefit a person with a real-world injury would experience.
What is the human dose-response relationship?
Human studies have used very different amounts and routes for very different problems. There is no validated human dosing regimen that tells us how exposure relates to benefit or risk across common use cases.
What does repeated human exposure look like?
Existing human reports are small and mostly short. They do not tell us what months of repeated exposure would look like in a large and varied population.
How important is the route?
The human research includes rectal, intra-articular, intravesical and intravenous exposure. FDA found no human studies using several routes commonly discussed in the marketplace, including the nominated subcutaneous route.
What interactions matter?
There is not a mature human evidence base describing interactions with prescription medicines, supplements or other research peptides.
How consistent are commercial products?
Product quality is a separate issue from the peptide's underlying biology. FDA has highlighted questions involving BPC-157 free base versus acetate, peptide-related impurities, aggregation and manufacturing characterisation.
What do we know about BPC-157 safety?
The most accurate answer is that the human safety picture is incomplete. That is different from saying BPC-157 is known to be dangerous, and it is also different from saying it has been demonstrated to be safe. The available human studies are simply too small and too short to define a broad safety profile.
Preclinical toxicology work has generally not shown an obvious severe-toxicity signal at the exposures tested. A formal rat and dog safety programme has been published, and the 2025 systematic review found no adverse effects across the preclinical safety studies it evaluated.
Human observations have so far been relatively reassuring in the narrow sense that the small published reports did not identify serious adverse events. The two-person IV pilot reported no side effects, and the interstitial-cystitis pilot reported none among its 12 participants. FDA also noted that no serious adverse events appeared to have been reported across the small human studies it reviewed.
That does not close the safety question. FDA found three adverse-event reports associated with BPC-157 in its reporting databases through December 2025, involving an injection-site reaction, shortness of breath and changes in pigmentation. FDA specifically noted that it could not establish that BPC-157 caused those events because the reports were limited and confounded.
There is also a product-quality issue. Peptides can contain synthesis-related impurities or form aggregates depending on manufacture, formulation and storage. FDA has raised immunogenicity and characterisation concerns around compounded BPC-157 products. That means safety depends not only on the biological molecule being discussed in a paper, but also on what is actually present in a real product.
In November 2026, Health Canada reported finding Sphingomonas aquatilis/melonis bacteria in one injectable peptide product seized from a retailer. The inventory included BPC-157 alone and in blends. The agency did not say that every listed product or batch was contaminated. This is evidence of a supply-chain quality hazard, not a clinical study of BPC-157. A research-use label does not establish sterility or suitability for human injection.
BPC-157 is not an FDA-approved medicine.
FDA reviewed BPC-157 free base and BPC-157 acetate at its July 2026 Pharmacy Compounding Advisory Committee meeting in the context of possible inclusion on the 503A bulk-drug-substances list. That compounding process is separate from FDA drug approval.
BPC-157 is listed under S0, Non-Approved Substances, on the 2026 World Anti-Doping Agency Prohibited List.
BPC-157 questions, answered simply
What is the BPC-157 peptide?
BPC-157 is a synthetic 15-amino-acid peptide, which is why it is also described as a pentadecapeptide. Its reported sequence is GEPPPGKPADDAGLV, and the BPC part of its name comes from Body Protection Compound.
What is in BPC-157?
BPC-157 consists of 15 amino acids arranged in the reported sequence GEPPPGKPADDAGLV. Modern BPC-157 used in research is synthesised rather than extracted from gastric juice. The peptide material may be presented in different chemical or finished-product forms, so identity and formulation should not be treated as interchangeable questions.
Has BPC-157 been tested in humans?
Yes, but only on a small scale. Human exposure has been reported in ulcerative-colitis development, a knee-pain chart review, an interstitial-cystitis pilot and a two-person intravenous safety study. That is enough to say human research exists, but not enough to say BPC-157 has a mature clinical evidence base.
Why is BPC-157 associated with tendon healing?
Several animal studies have deliberately injured Achilles tendons or tendon-to-bone attachments and then measured healing. Researchers reported improvements in collagen organisation, mechanical strength and functional recovery in treated animals. Laboratory work has also found effects on tendon fibroblast migration and survival.
Is there a research-backed BPC-157 starting dose?
There is no validated general human starting dose in the clinical literature. Human studies used very different amounts and routes because they were investigating different conditions. The study-protocol table on this page shows those published exposures so you can see where the numbers came from, rather than presenting one of them as a universal personal-use recommendation.
How long does BPC-157 stay in the body?
Formal animal pharmacokinetic research found an elimination half-life of less than 30 minutes after intravenous administration in rats and dogs. The tiny human IV pilot also reported plasma concentrations falling rapidly. The relationship between that short measured exposure and the longer biological effects reported in animal research remains an open translational question.
Is BPC-157 FDA approved?
No. BPC-157 is not an FDA-approved drug. FDA has separately been considering BPC-157-related bulk substances through the pharmacy-compounding process, including a July 2026 advisory committee review. That process should not be confused with approval of BPC-157 as a medicine.
Is BPC-157 banned in sport?
Yes for athletes governed by WADA rules. BPC-157 appears under S0, Non-Approved Substances, on the 2026 WADA Prohibited List.
See how Orentra reviews peptide research
Human, animal and laboratory findings are not treated as equivalent evidence. See how we select sources, assess studies, apply evidence labels and keep guides up to date.
Sources
These are the papers and regulatory sources used to build this page. Each summary explains what the source adds so you can decide which papers are worth opening yourself.
One seized injectable peptide product tested positive for bacteria; BPC-157 was among the retailer's listed products, without a claim that all products were contaminated.
Open source →A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPCOne of the early publications describing the gastric BPC research programme and the 15-amino-acid BPC-157 fragment. Useful for understanding where the compound came from and why gastrointestinal research appears so prominently in its history.
Open source →Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growthA rat Achilles tendon-transection study that also examined cultured tendon cells. Researchers reported improved tendon mechanics, function and tissue organisation in treated rats.
Open source →Achilles detachment in rat and stable gastric pentadecapeptide BPC 157Researchers detached the Achilles tendon from the calcaneal bone. BPC-157-treated rats showed improvements in functional, biomechanical and tissue-healing measurements, including collagen organisation.
Open source →Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157Used a complete quadriceps-muscle transection model. Researchers reported improvements in biomechanical strength, walking function, muscle regeneration and tissue appearance over a 72-day observation period.
Open source →Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the ratExamined a gastrocnemius muscle-crush model. Treated rats showed improvements in macroscopic appearance, tissue findings, muscle function and several injury-related enzyme measures.
Open source →Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the ratStudied surgically transected medial collateral ligaments. Researchers reported improved functional, biomechanical, macroscopic and histological healing across several experimental administration routes.
Open source →The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migrationInvestigated how tendon fibroblasts behave in the presence of BPC-157. Researchers reported increased migration, spreading and survival under stress, with changes involving FAK-paxillin signalling.
Open source →Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tractReviews gastrointestinal BPC-157 research covering oesophageal, stomach, intestinal, liver and pancreatic injury models and helps explain the peptide's original research context.
Open source →Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157Reviews BPC-157 in the context of ulcerative-colitis research and the earlier PL-14736 clinical-development programme.
Open source →Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblastsFound increased growth-hormone receptor expression in BPC-157-treated tendon fibroblasts and explored how that changed subsequent cellular responses to growth hormone.
Open source →Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulationInvestigated angiogenesis and reported effects involving vessel formation, recovery of blood flow and activation of the VEGFR2-Akt-eNOS signalling pathway.
Open source →Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in RatsStudied severe injury at the junction between quadriceps muscle and tendon. Researchers reported improvements in structural healing, muscle atrophy and functional recovery.
Open source →Intra-Articular Injection of BPC 157 for Multiple Types of Knee PainRetrospective chart review of 17 identified patients. Of the 12 contacted participants who had received BPC-157 alone, 11 reported significant improvement. There was no placebo group or standardised objective measure of repair.
Open source →Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogsA formal ADME study reporting a plasma half-life below 30 minutes, linear pharmacokinetics, rapid peptide-fragment metabolism and urinary and biliary elimination.
Open source →Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot StudyTwelve women received a total of 10 mg during a bladder procedure. All reported substantial symptom improvement and no adverse events were reported. The study was small and uncontrolled.
Open source →Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic ReviewScreened 544 records and included 36 musculoskeletal studies, 35 preclinical and one clinical. The review found repeated positive findings in animal muscle, tendon, ligament and bone models while highlighting the limited human evidence.
Open source →Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal HealingReviews proposed repair mechanisms, including VEGFR2, nitric-oxide signalling, fibroblast activity and neuromuscular effects, alongside the limitations of the current clinical evidence.
Open source →Safety of Intravenous Infusion of BPC157 in Humans: A Pilot StudyTwo adults received 10 mg and then 20 mg intravenous infusions on consecutive days. Researchers reported no side effects or clinically meaningful changes in the measured biomarkers. The sample is far too small to establish general human safety.
Open source →BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development BarriersA recent review of BPC-157 chemistry, pharmacokinetics, formulation and clinical-development barriers. It argues that the peptide has substantial preclinical activity but lacks validated human dosing, mature pharmaceutical development and Phase II evidence.
Open source →Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical studyCompared control, BPC-157, TB-500 and combined treatment after Achilles repair. BPC-157 showed some favourable measures, while TB-500 produced the clearest statistically significant biomechanical result. The combination did not show an obvious additive benefit.
Open source →FDA Briefing Document for BPC-157-Related Bulk Drug SubstancesFDA reviewed BPC-157 chemistry, clinical exposure, nonclinical evidence, safety reports, product-quality issues and the earlier ulcerative-colitis development programme for its July 2026 Pharmacy Compounding Advisory Committee meeting.
Open source →2026 World Anti-Doping Agency Prohibited ListLists BPC-157 under S0, Non-Approved Substances, which is relevant to athletes subject to WADA anti-doping rules.
Open source →Solid-Phase Peptide Synthesis: An IntroductionA general introduction to solid-phase peptide synthesis, the standard chemical approach used to build many synthetic peptides by assembling amino acids step by step on a solid support.
Open source →Building Parity Between Brand and Generic Peptide Products: Regulatory and Scientific Considerations for Quality of Synthetic PeptidesExplains why synthetic peptide quality depends on more than headline purity, including structural characterisation, manufacturing controls, peptide-related impurities, aggregates and storage-related changes.
Open source →Research reviewed through November 2026.